Redhill Biopharma

RDHL

Current ValuationThe current P/E ratio is -1.09, below the reasonable range, cheaper than 83.52% of the time in the past 3 years, and the industry ranks 113/255, the industry Median -1.12.

-1.09xP/E
Stock price$0.43Earnings per share$-0.39

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0285684112

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
GSKUSGSK
--16.02%$99.32B
TAKUSTakeda Pharmaceutical Company
-60.94x146.63%$63.66B
BAYRYUSBayer
-24.97x--$50.30B
BAYZFUSBayer Aktiengesellschaft
-25.04x--$50.44B
VTRSUSViatris
-52.49x107.68%$21.56B
ELANUSElanco Animal Health
-56.87x130.52%$11.32B
AXSMUSAxsome Therap
-39.22x20.27%$7.52B
VREOFUSVIREO GROWTH INC
-109.29x--$7.33B
CURLFUSCuraleaf Holdings, Inc.
-124.76x--$6.49B
MANEUSVeraDermics
-57.62x97.44%$6.01B
BLTEUSBelite Bio
-58.51x29.87%$5.99B
DFTXUSDefinium Therapeutics
-14.47x54.55%$5.12B
EWTXUSEdgewise Therapeutics
-22.30x187.50%$4.40B
RGCUSRegencell Bioscience
-307.82x--$3.60B
AMLXUSAmylyx Pharmaceuticals
-23.16x1.76%$3.52B
ELVNUSEnliven Therapeutics
-30.97x5.59%$3.28B
TARSUSTarsus Pharmaceuticals
-68.03x345.28%$3.16B
MBXUSMBX Biosciences
-25.01x31.12%$2.61B
BHCUSBausch Health
-2.36x569.84%$2.59B
SUPNUSSupernus Pharma
-21.73x66.18%$2.39B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.